Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLY J PARLING-LYNCH

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1215936158
CMS profile
236155
Location
NORTON SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,962.01

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,867.01 153
Education $95.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLY J PARLING-LYNCH

NPI 1215936158 · CMS profile ID 236155

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NORTON SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215936158?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLY J PARLING-LYNCH, NPI 1215936158, CMS profile ID 236155. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215936158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KELLY J PARLING-LYNCH, NPI 1215936158, CMS profile ID 236155. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215936158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KELLY J PARLING-LYNCH, NPI 1215936158, CMS profile ID 236155, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215936158?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $2,962.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $28.6708/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992864289 CMS
PharmaEssentia USA Corporation $23.0908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059316561 CMS
GlaxoSmithKline, LLC. $19.1208/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003511685 CMS
Eisai Inc. $24.8008/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318169 CMS
Genentech USA, Inc. $11.6008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425627 CMS
Gilead Sciences, Inc. $16.7208/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025938921 CMS
Pharmacyclics LLC, An AbbVie Company $17.1208/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998292453 CMS
Genentech USA, Inc. $21.5708/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425591 CMS
Seagen Inc. $16.2208/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995645763 CMS
Regeneron Healthcare Solutions, Inc. $17.2808/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999350243 CMS
Celgene Corporation $3.3008/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015310743 CMS
AstraZeneca Pharmaceuticals LP $14.1207/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015895763 CMS
Pharmacyclics LLC, An AbbVie Company $20.0407/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998292451 CMS
Daiichi Sankyo Inc. $26.7707/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006400167 CMS
ABBVIE INC. $18.5107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998077779 CMS
Eisai Inc. $4.2607/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318167 CMS
Eisai Inc. $0.5907/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318165 CMS
Eisai Inc. $9.5607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318171 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.8707/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000695355 CMS
Merck Sharp & Dohme LLC $28.9907/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048611027 CMS
PFIZER INC. $13.0207/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050519939 CMS
Rigel Pharmaceuticals, Inc. $11.6106/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033411883 CMS
Genentech USA, Inc. $0.1306/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425567 CMS
Genentech USA, Inc. $29.0306/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425571 CMS
Celgene Corporation $0.2506/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015310707 CMS
Celgene Corporation $1.5506/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015310713 CMS
JAZZ PHARMACEUTICALS INC. $15.4706/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058408317 CMS
SERVIER PHARMACEUTICALS LLC $15.7006/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055090085 CMS
Genentech USA, Inc. $18.0806/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425595 CMS
Alexion Pharmaceuticals, Inc. $16.2806/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016993803 CMS
AstraZeneca Pharmaceuticals LP $13.1206/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011368523 CMS
Pharmacyclics LLC, An AbbVie Company $13.7006/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998292449 CMS
Celgene Corporation $4.8506/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015310667 CMS
GlaxoSmithKline, LLC. $16.5506/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003511403 CMS
PFIZER INC. $12.9905/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049492995 CMS
Foundation Medicine, Inc. $21.4805/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058788537 CMS
Regeneron Healthcare Solutions, Inc. $33.3605/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999350237 CMS
Lilly USA, LLC $13.1705/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031741717 CMS
Eisai Inc. $24.7505/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318175 CMS
PFIZER INC. $12.4805/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049436373 CMS
Merck Sharp & Dohme LLC $30.5005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048611031 CMS
Novartis Pharmaceuticals Corporation $16.3305/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992864287 CMS
Exelixis Inc. $34.5305/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044554301 CMS
Gilead Sciences, Inc. $13.4705/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026035657 CMS
Mylan Institutional Inc. $19.3405/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039007987 CMS
Incyte Corporation $19.2005/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044472513 CMS
Merck Sharp & Dohme LLC $24.1305/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048611023 CMS
Daiichi Sankyo Inc. $21.5805/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006417701 CMS
Genentech USA, Inc. $15.9905/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425619 CMS
Celgene Corporation $15.8105/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015310609 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,388.08 214
PY2020 $617.59 34
PY2021 $281.65 9
PY2022 $3,534.83 151
PY2023 $2,962.01 154
PY2024 $3,363.04 154
PY2025 $3,760.01 153

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $118,037.53 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $379.35 12/31/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202535139
Principal investigator 1 ABBVIE INC. $350.00 12/31/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202535383
Principal investigator 1 ABBVIE INC. $777.95 12/31/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202535385
Principal investigator 1 ABBVIE INC. $8,526.60 12/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202526512
Principal investigator 1 ABBVIE INC. $3,568.40 12/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202526514
Principal investigator 1 ABBVIE INC. $175.00 12/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202526516
Principal investigator 1 ABBVIE INC. $554.35 12/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202526518
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,596.25 12/03/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF WESTERN MICHIGAN, PC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185546041
Principal investigator 1 Genentech, Inc. $23,076.00 12/03/2025 Non-covered Recipient Entity
CANCER + HEMATOLOGY CENTERS OF WESTERN MICHIGAN
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211583055
Principal investigator 1 ABBVIE INC. $729.35 11/05/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202521779
Principal investigator 1 ABBVIE INC. $350.00 11/05/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202521781
Principal investigator 1 ABBVIE INC. $12,469.95 11/05/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202521935
Principal investigator 1 Genentech, Inc. $11,521.00 11/04/2025 Non-covered Recipient Entity
CANCER + HEMATOLOGY CENTERS OF WESTERN MICHIGAN
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211583049
Principal investigator 1 Genentech, Inc. $7,036.20 10/28/2025 Non-covered Recipient Entity
CANCER + HEMATOLOGY CENTERS OF WESTERN MICHIGAN
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211583045
Principal investigator 1 ABBVIE INC. $10,547.55 10/09/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202514567
Principal investigator 1 ABBVIE INC. $554.35 09/30/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512804
Principal investigator 1 ABBVIE INC. $242.00 09/30/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512806
Principal investigator 1 ABBVIE INC. $175.00 09/30/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512810
Principal investigator 1 ABBVIE INC. $379.35 09/30/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512812
Principal investigator 1 ABBVIE INC. $554.35 09/30/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512814
Principal investigator 1 ABBVIE INC. $644.80 09/30/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202512816
Principal investigator 1 ABBVIE INC. $554.35 09/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202508890
Principal investigator 1 ABBVIE INC. $20,281.05 09/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202508892
Principal investigator 1 ABBVIE INC. $439.10 09/04/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202508894
Principal investigator 1 Genentech, Inc. $1,259.23 07/29/2025 Non-covered Recipient Entity
CANCER + HEMATOLOGY CENTERS OF WESTERN MICHIGAN
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211583038
Principal investigator 1 Genentech, Inc. $9,296.00 07/16/2025 Non-covered Recipient Entity
CANCER + HEMATOLOGY CENTERS OF WESTERN MICHIGAN
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211583042